Research programme: histone methyltransferase inhibitors - Epizyme
Alternative Names: CARM1 inhibitors; coactivator-associated arginine methyltransferase 1 inhibitors; EPZ 020411; HMT 2; HMT 3; HMT inhibitors; PRMT1 inhibitors; PRMT3 inhibitors; PRMT6 inhibitors; PRMT8 inhibitors; Protein arginine methyltransferase 1 inhibitors; Protein arginine methyltransferase 3 inhibitors; Protein arginine methyltransferase 6 inhibitors; Protein arginine methyltransferase 8 inhibitorsLatest Information Update: 28 Oct 2024
At a glance
- Originator Epizyme
- Developer Celgene International SARL; Epizyme
- Class Antineoplastics; Pyrazoles
- Mechanism of Action Histone methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 28 Oct 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 14 Oct 2022 Research programme: histone methyltransferase inhibitors is still in preclinical trials for Haematological malignancies in USA (Epizyme pipeline, October 2022)